Eguia A, Bagan L, Cardona F. Review and update on drugs related to the development of osteonecrosis of the jaw. Med Oral Patol Oral Cir Bucal. 2020 Jan 1;25 (1):e71-83.


1. Marx RE. Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-7.


2. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of Bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-34.


3. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, et al. Cancer chemotherapy induced avascular jaw osteonecrosis: series of 10 cases. J Oral Pathol Med. 2005;34:120-3.


4. McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: A systematic review. Oral Dis. 2018;24:527-536.


5. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:433-41.


6. McMahon RE, Bouquot JE, Glueck CJ, Griep JA, Adams WR, Spolnik KJ, et al. Staging bisphosphonate-related osteonecrosis of the jaw should include early stages of disease. J Oral Maxillofac Surg. 2007;65:1899-900.


7. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. J Oral Maxillofac Surg. 2009;67:2-12.


8. Mawardi H, Treister N, Richardson P, Anderson K, Munshi N, Faiella RA, et al. Sinus tracts-an early sign of bisphosphonate associated osteonecrosis of the jaws?. J Oral Maxillofac Surg. 2009;67:593-601.


9. Bagan JV, Jimenez Y, Diaz JM, Murillo J, Sanchis JM, Poveda R, et al. Osteonecrosis of the jaws in intravenous bisphosphonate use: proposal for a modification of the clinical classification. Oral Oncol. 2009;45:645-6.


10. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab. 2010;28:365-83.


11. Bagan JV, Hens-Aumente E, Leopoldo-Rodado M, Poveda-Roda R, Bagan L. Bisphosphonate-related osteonecrosis of the jaws: study of the staging system in a series of clinical cases. Oral Oncol. 2012;48:753-7.


12. Bedogni A, Fusco V, Agrillo A, Campisi G. Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ). Oral Dis. 2012;18:621-3.
PMid:22353421 PMCid:PMC3443365


13. Patel S, Choyee S, Uyanne J, Nguyen AL, Lee P, Sedghizadeh PP, et al. Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines. Oral Dis. 2012;18:625-32.


14. Schiodt M, Reibel J, Oturai P, Kofod T. Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117:204-13.


15. Franco S, Miccoli S, Limongelli L, Tempesta A, Favia G, Maiorano E, et al. New dimensional staging of bisphosphonate-related osteonecrosis of the jaw allowing a guided surgical treatment protocol: long-term follow-up of 266 lesions in neoplastic and osteoporotic patients from the university of bari. Int J Dent. 2014;2014:935657.
PMid:24995017 PMCid:PMC4068095


16. Mawardi H, Woo SB. Medication-related osteonecrosis of the jaws, stage 0--do we need stage 0 any more?. J Oral Maxillofac Surg. 2015;73:797-7.


17. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab. 2017;35:6-19.


18. Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018;69:177-87.


19. Jacobsen C, Zemann W, Obwegeser JA, Grätz KW, Metzler P. The phosphorous necrosis of the jaws and what can we learn from the past: a comparison of "phossy" and "bisphossy" jaw. Oral Maxillofac Surg. 2014;18:31-7.


20. Pollock RA, Brown TW Jr, Rubin DM. "Phossy Jaw" and "Bis-phossy Jaw" of the 19th and the 21st Centuries: The Diuturnity of John Walker and the Friction Match. Craniomaxillofac Trauma Reconstr. 2015;8:262-70.
PMid:27053988 PMCid:PMC4812794


21. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014;72:1938-56.


22. Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, et al. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. J Clin Densitom. 2017;20:8-24.


23. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30:3-23.


24. Yeo AC, Lye KW, Poon CY. Bisphosphonate-related osteonecrosis of the jaws. Singapore Dent J. 2005;27:36-40.


25. Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg. 2010;48:221-3.


26. Van Poznak C. Osteonecrosis of the jaw and bevacizumab therapy. Breast Cancer Res Treat. 2010;122:189-91.
PMid:20464477 PMCid:PMC2975671


27. Brunello A, Saia G, Bedogni A, Scaglione D, Basso U. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone. 2009;44:173-5.


28. Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2017;10:CD012432.
PMid:28983908 PMCid:PMC6485859


29. Tai TW, Su FC, Chen CY, Jou IM, Lin CF. Activation of p38 MAPK-regulated Bcl-xL signaling increases survival against zoledronic acid-induced apoptosis in osteoclast precursors. Bone. 2014;67:166-74.


30. Quispe D, Shi R, Burton G. Osteonecrosis of the jaw in patients with metastatic breast cancer: ethnic and socio-economic aspects. Breast J. 2011;17:510-3.


31. Hamadeh IS, Ngwa BA, Gong Y. Drug induced osteonecrosis of the jaw. Cancer Treat Rev. 2015;41:455-64.


32. Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010;68:243-53.


33. Krstevska S, Stavric SG, Cevrevska L, Georgjievski B, Karanfilski O, Sotirova T, et al. Osteonecrosis of the Jaw After Bisphosphonates Treatment in Patients with Multiple Myeloma. Med Arch. 2015;69:367-70.
PMid:26843726 PMCid:PMC4720463


34. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009;27:5356-62.


35. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008;44:857-69.


36. Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014;19:403-10.


37. Mauri D, Valachis A, Polyzos IP, Polyzos NP, Kamposioras K, Pesce LL. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Res Treat. 2009;116:433-9.


38. Deeks ED. Denosumab: A Review in Postmenopausal Osteoporosis. Drugs Aging. 2018;35:163-73.


39. Iranikhah M, Deas C, Murphy P, Freeman MK. Effects of Denosumab After Treatment Discontinuation: A Review of the Literature. Consult Pharm. 2018;33:142-51.


40. Aljohani S, Gaudin R, Weiser J, Tröltzsch M, Ehrenfeld M, Kaeppler G, et al. Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series. J Craniomaxillofac Surg. 2018;46:1515-25.


41. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48:677-92.


42. Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwiński E, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27:694-701.
PMid:22113951 PMCid:PMC3415620


43. Mander KA, Finnie JW. Tumor angiogenesis, anti-angiogenic therapy and chemotherapeutic resistance. Aust Vet J. 2018;96:371-8.


44. Pimolbutr K, Porter S, Fedele S. Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature. Biomed Res Int. 2018;2018:8071579.
PMid:29850569 PMCid:PMC5937620


45. Chang J, Hakam AE, McCauley LK. Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw. Curr Osteoporos Rep. 2018;16:584-95.


46. Aldridge SE, Lennard TW, Williams JR, Birch MA. Vascular endothelial growth factor receptors in osteoclast differentiation and function. Biochem Biophys Res Commun. 2005;335:793-8.


47. Pazianas M. Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst. 2011;103:232-40.


48. Zarringhalam P, Brizman E, Shakib K. Medication-related osteonecrosis of the jaw associated with aflibercept. Br J Oral Maxillofac Surg. 2017;55:314-5.


49. Won AM, Boddu P, Otun AO, Aponte-Wesson R, Chambers M. Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;126:e208-11.


50. Abel Mahedi Mohamed H, Nielsen CEN, Schiodt M. Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125:157-63.


51. Viviano M, Rossi M, Cocca S. A rare case of osteonecrosis of the jaw related to imatinib. J Korean Assoc Oral Maxillofac Surg. 2017;43:120-4.
PMid:28462197 PMCid:PMC5410424


52. Patel V, Sproat C, Kwok J, Tanna N. Axitinib-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;124:e257-60.


53. Garuti F, Camelli V, Spinardi L, Bucci L, Trevisani F. Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. Tumori. 2016;102(Suppl. 2).


54. Marino R, Orlandi F, Arecco F, Gandolfo S, Pentenero M. Osteonecrosis of the jaw in a patient receiving cabozantinib. Aust Dent J. 2015;60:528-31.


55. Magremanne M, Lahon M, De Ceulaer J, Reychler H. Unusual bevacizumab-related complication of an oral infection. J Oral Maxillofac Surg. 2013;71:53-5.


56. Wolfe RM, Ang DC. Biologic Therapies for Autoimmune and Connective Tissue Diseases. Immunol Allergy Clin North Am. 2017;37:283-99.


57. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010;11:180-210.


58. Favia G, Tempesta A, Limongelli L, Crincoli V, Iannone F, Lapadula G, Maiorano E. A Case of Osteonecrosis of the Jaw in a Patient with Crohn's Disease Treated with Infliximab. Am J Case Rep. 2017;18:1351-6.
PMid:29257800 PMCid:PMC5737229


59. Cassoni A, Romeo U, Terenzi V, Della Monaca M, Rajabtork Zadeh O, Raponi I, et al. Adalimumab: Another Medication Related to Osteonecrosis of the Jaws?. Case Rep Dent. 2016;2016:2856926.
PMid:27088019 PMCid:PMC4819088


60. Preidl RH, Ebker T, Raithel M, Wehrhan F, Neukam FW, Stockmann P. Osteonecrosis of the jaw in a Crohn's disease patient following a course of Bisphosphonate and Adalimumab therapy: a case report. BMC Gastroenterol. 2014;14:6.
PMid:24400722 PMCid:PMC3890650


61. Keribin P, Guerrot D, Jardin F, Moizan H. Osteonecrosis of the Jaw in a Patient Presenting With Post-Transplantation Lymphoproliferative Disorder Treated With Rituximab: A Case Report. J Oral Maxillofac Surg. 2017;75:2599-605.


62. Allegra A, Oteri G, Alonci A, Bacci F, Penna G, Minardi V, et al. Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab. J Craniomaxillofac Surg. 2014;42:279-82.


63. Davignon JL, Rauwel B, Degboé Y, Constantin A, Boyer JF, Kruglov A, Cantagrel A. Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review. Arthritis Res Ther. 2018;20:229.
PMid:30314507 PMCid:PMC6235207


64. Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine. 2012;41:183-90.
PMid:22169965 PMCid:PMC3712793


65. Powell C, Chang C, Gershwin ME. Current concepts on the pathogenesis and natural history of steroid-induced osteonecrosis. Clin Rev Allergy Immunol. 2011;41:102-13.


66. Berti-Couto SA, Vasconcelos AC, Iglesias JE, Figueiredo MA, Salum FG, Cherubini K. Diabetes mellitus and corticotherapy as risk factors for alendronate-related osteonecrosis of the jaws: a study in Wistar rats. Head Neck. 2014;36:84-93.


67. Di Fede O, Bedogni A, Giancola F, Saia G, Bettini G, Toia F, et al. BRONJ in patients with rheumatoid arthritis: a multicenter case series. Oral Dis. 2016;22:543-8.


68. Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA. 2018;320:1360-72.


69. van Dalen EC, van As JW, de Camargo B. Methotrexate for high-grade osteosarcoma in children and young adults. Cochrane Database Syst Rev. 2011;5:CD006325.


70. Furukawa S, Oobu K, Moriyama M, Kawano S, Sako S, Hayashida JN, et al. Oral Methotrexate-related Lymphoproliferative Disease Presenting with Severe Osteonecrosis of the Jaw: A Case Report and Literature Review. Intern Med. 2018;57:575-81.
PMid:29225245 PMCid:PMC5849556


71. Furudate K, Satake A, Narita N, Kobayashi W. Methotrexate-Related Lymphoproliferative Disorder in Patients With Osteonecrosis of the Jaw: A 3-Case Report and Literature Review. J Oral Maxillofac Surg. 2018;76:97-111.


72. Henien M, Carey B, Hullah E, Sproat C, Patel V. Methotrexate-associated osteonecrosis of the jaw: A report of two cases. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;124:e283-7.


73. Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. Eur J Med Chem. 2018;158:502-16.


74. Chan ES, Cronstein BN. Mechanisms of action of methotrexate. Bull Hosp Jt Dis. 2013;71:S5-8.


75. Kezic A, Popovic L, Lalic K. mTOR Inhibitor Therapy and Metabolic Consequences: Where Do We Stand?. Oxid Med Cell Longev. 2018;2018:2640342.
PMid:30034573 PMCid:PMC6035806


76. Konings IR, Verweij J, Wiemer EA, Sleijfer S. The applicability of mTOR inhibition in solid tumors. Curr Cancer Drug Targets. 2009;9:439-50.


77. Giancola F, Campisi G, Lo Russo L, Muzio LL, Di Fede O. Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report?. Ann Stomatol (Roma). 2013;4:20-1.


78. Omarini C, Filieri ME, Depenni R, Grizzi G, Cascinu S, Piacentini F. Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. Breast J. 2017;23:610-1.


79. Nifosì AF, Nifosì L, Nifosì G. Osteonecrosis of the Jaw in a Patient Treated with Denosumab and Temsirolimus. SAJ Case Rep. 2017;4:401.


80. Kim DW, Jung YS, Park HS, Jung HD. Osteonecrosis of the jaw related to everolimus: a case report. Br J Oral Maxillofac Surg. 2013;51:e302-4.


81. Faes S, Santoro T, Demartines N, Dormond O. Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy. Cancers (Basel). 2017;9:E152.
PMid:29104248 PMCid:PMC5704170


82. Yamamoto D, Tsubota Y, Utsunomiya T, Sueoka N, Ueda A, Endo K, et al. Osteonecrosis of the jaw associated with everolimus: A case report. Mol Clin Oncol. 2017;6:255-7.
PMid:28357105 PMCid:PMC5351763


83. Owosho AA, Scordo M, Yom SK, Randazzo J, Chapman PB, Huryn JM, et al. Osteonecrosis of the jaw a new complication related to Ipilimumab. Oral Oncol. 2015;51:e100-1.
PMid:26421864 PMCid:PMC4784100


84. Nicolatou-Galitis O, Galiti D, Moschogianni M, Sachanas S, Edwards BJ, Migliorati CA, et al. Osteonecrosis of the jaw in a patient with acute myeloid leukemia, who received azacitidine. J Cancer Metasta Treat. 2016;2:220-3.